991 reports of this reaction
1.7% of all THALIDOMIDE reports
#11 most reported adverse reaction
CONSTIPATION is the #11 most commonly reported adverse reaction for THALIDOMIDE, manufactured by Celgene Corporation. There are 991 FDA adverse event reports linking THALIDOMIDE to CONSTIPATION. This represents approximately 1.7% of all 58,680 adverse event reports for this drug.
THALIDOMIDE has an overall safety score of 95 out of 100. Patients taking THALIDOMIDE who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for THALIDOMIDE, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for THALIDOMIDE:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 991 FDA reports for THALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 1.7% of all adverse event reports for THALIDOMIDE, making it a notable side effect.
If you experience constipation while taking THALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.